Cargando…

Abstract 31 Testing of Cord Blood Units for Non-Hematopoietic Markers

INTRODUCTION: Cord blood units (CBU) are tested at banking for markers relevant to donor safety (infectious disease markers) and hematopoietic stem cell transplantation (cellularity and HLA typing). As CBUs are being increasingly used for new, non-transplant purposes, additional markers are sometime...

Descripción completa

Detalles Bibliográficos
Autores principales: Frenet, Emeline Masson, Watanabe, Chiseko, Bentsen, Helen, Chowtee, Bryana, Liu, WenJun, Romeo, Cynthia, Sung, Dorothy, Jimenez, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446944/
http://dx.doi.org/10.1093/stcltm/szac057.031
_version_ 1784783752001486848
author Frenet, Emeline Masson
Watanabe, Chiseko
Bentsen, Helen
Chowtee, Bryana
Liu, WenJun
Romeo, Cynthia
Sung, Dorothy
Jimenez, Alexandra
author_facet Frenet, Emeline Masson
Watanabe, Chiseko
Bentsen, Helen
Chowtee, Bryana
Liu, WenJun
Romeo, Cynthia
Sung, Dorothy
Jimenez, Alexandra
author_sort Frenet, Emeline Masson
collection PubMed
description INTRODUCTION: Cord blood units (CBU) are tested at banking for markers relevant to donor safety (infectious disease markers) and hematopoietic stem cell transplantation (cellularity and HLA typing). As CBUs are being increasingly used for new, non-transplant purposes, additional markers are sometimes needed for CBU selection. OBJECTIVE: We describe here our procedure for testing CBU, looking for specific NK cell characteristics: KIR haplotype B (associated with more activating KIRs), and Fc gamma receptor III A (FCGR3A) 158 V/V (presence of a homozygous valine in position 158) polymorphism (which has a higher affinity for IgG), as requested by some of our clients for non-transplant studies. METHODS: First, a list of eligible CBUs was established, based on the order specifications. Testing was requested from an outside lab (Histogenetics, Ossining, New York). As CBU DNA is a precious resource, we wanted to limit the number of new samples to be sent by first testing leftover samples from HLA typing, then sending additional samples to the lab, to reach the required number of CBUs. Testing was done sequentially (Figure 1): first, KIR typing, then FCGR3A polymorphism on the CBU with KIR B haplotype. RESULTS: A total of 216 samples were selected for KIR testing (130 from stored DNA and 86 from newly sent DNA); 154 (71%) were found to have at least one B haplotype receptor. For those, FCGR3A polymorphism was tested; 60 samples (39%) were F/F, 70 (46%) F/V, and 23 (15%) V/V (Figure 1), in line with expected frequencies from the literature. Average TAT for KIR testing was 13 days and an additional 18 days for FCGRA3. DISCUSSION: Performing additional testing can easily be integrated into a bank’s routine and help select CBU for purposes other than transplantation. When several markers are needed, sequential testing is an efficient and cost-saving method.
format Online
Article
Text
id pubmed-9446944
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94469442022-09-06 Abstract 31 Testing of Cord Blood Units for Non-Hematopoietic Markers Frenet, Emeline Masson Watanabe, Chiseko Bentsen, Helen Chowtee, Bryana Liu, WenJun Romeo, Cynthia Sung, Dorothy Jimenez, Alexandra Stem Cells Transl Med Cord Blood Bank Management, Administration, and Sustainability INTRODUCTION: Cord blood units (CBU) are tested at banking for markers relevant to donor safety (infectious disease markers) and hematopoietic stem cell transplantation (cellularity and HLA typing). As CBUs are being increasingly used for new, non-transplant purposes, additional markers are sometimes needed for CBU selection. OBJECTIVE: We describe here our procedure for testing CBU, looking for specific NK cell characteristics: KIR haplotype B (associated with more activating KIRs), and Fc gamma receptor III A (FCGR3A) 158 V/V (presence of a homozygous valine in position 158) polymorphism (which has a higher affinity for IgG), as requested by some of our clients for non-transplant studies. METHODS: First, a list of eligible CBUs was established, based on the order specifications. Testing was requested from an outside lab (Histogenetics, Ossining, New York). As CBU DNA is a precious resource, we wanted to limit the number of new samples to be sent by first testing leftover samples from HLA typing, then sending additional samples to the lab, to reach the required number of CBUs. Testing was done sequentially (Figure 1): first, KIR typing, then FCGR3A polymorphism on the CBU with KIR B haplotype. RESULTS: A total of 216 samples were selected for KIR testing (130 from stored DNA and 86 from newly sent DNA); 154 (71%) were found to have at least one B haplotype receptor. For those, FCGR3A polymorphism was tested; 60 samples (39%) were F/F, 70 (46%) F/V, and 23 (15%) V/V (Figure 1), in line with expected frequencies from the literature. Average TAT for KIR testing was 13 days and an additional 18 days for FCGRA3. DISCUSSION: Performing additional testing can easily be integrated into a bank’s routine and help select CBU for purposes other than transplantation. When several markers are needed, sequential testing is an efficient and cost-saving method. Oxford University Press 2022-09-06 /pmc/articles/PMC9446944/ http://dx.doi.org/10.1093/stcltm/szac057.031 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cord Blood Bank Management, Administration, and Sustainability
Frenet, Emeline Masson
Watanabe, Chiseko
Bentsen, Helen
Chowtee, Bryana
Liu, WenJun
Romeo, Cynthia
Sung, Dorothy
Jimenez, Alexandra
Abstract 31 Testing of Cord Blood Units for Non-Hematopoietic Markers
title Abstract 31 Testing of Cord Blood Units for Non-Hematopoietic Markers
title_full Abstract 31 Testing of Cord Blood Units for Non-Hematopoietic Markers
title_fullStr Abstract 31 Testing of Cord Blood Units for Non-Hematopoietic Markers
title_full_unstemmed Abstract 31 Testing of Cord Blood Units for Non-Hematopoietic Markers
title_short Abstract 31 Testing of Cord Blood Units for Non-Hematopoietic Markers
title_sort abstract 31 testing of cord blood units for non-hematopoietic markers
topic Cord Blood Bank Management, Administration, and Sustainability
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446944/
http://dx.doi.org/10.1093/stcltm/szac057.031
work_keys_str_mv AT frenetemelinemasson abstract31testingofcordbloodunitsfornonhematopoieticmarkers
AT watanabechiseko abstract31testingofcordbloodunitsfornonhematopoieticmarkers
AT bentsenhelen abstract31testingofcordbloodunitsfornonhematopoieticmarkers
AT chowteebryana abstract31testingofcordbloodunitsfornonhematopoieticmarkers
AT liuwenjun abstract31testingofcordbloodunitsfornonhematopoieticmarkers
AT romeocynthia abstract31testingofcordbloodunitsfornonhematopoieticmarkers
AT sungdorothy abstract31testingofcordbloodunitsfornonhematopoieticmarkers
AT jimenezalexandra abstract31testingofcordbloodunitsfornonhematopoieticmarkers